Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

Collaboration Marks First At-Scale Deployment of AI Technologies into Leading Commercial BiobankBOSTON and HUNTSVILLE, Ala, Jan. 23, 2025, a leading biospecimens and specialty lab testing company, to ...

Scientists at the University of Virginia have uncovered how different exercise intensifies the impact of the hunger hormone ghrelin in the body.

To tackle a backlog in toxicity testing, US federal scientists are modernizing programs with high-throughput assays and AI.

The proof-of-concept demonstrates the power of pairing AI with lab orchestration solutions to automate molecular screening ...

ImmunoPrecise has outperformed the broader market in a spectacular fashion. As of now, IPA’s YTD performance stands at +81.64%, a staggering increase compared to the S&P 500’s YTD performance of just ...

NATICK, MASSACHUSETTS / ACCESS Newswire / January 22, 2025 / VALID, a Techbio startup dedicated to reshaping drug discovery ...

VERSES AI Inc., a cognitive computing company specializing in next-generation intelligent systems, has shared preliminary results on its variant of the “Atari 100K Challenge” a leading AI industry ...

We recently compiled a list of the 10 AI News You Should Not Miss. In this article, we are going to take a look at where ...

The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...